Global Hunter (GBLHF.PK)
Molybdenum is a natural occurring metal. On the Periodic Table of Elements, it is element number forty-two. On the Periodic Table of Elements, Molybdenum is a transition metal, which means it is an incomplete sub-shell. Molybdenum was discovered by a Swedish Chemist, in 1778. He found molybdenum in a mineral that was confused as a lead compound. Molybdenum was then isolated in 1781 by another Swedish Chemist. Molybdenum is typically found as a byproduct of mining and the processing of copper. As a metal, molybdenum is used to make missile and aircraft parts, and molybdenum is also used with nuclear power, but mostly molybdenum is used with alloying steel.
Global Hunter’s focus is on strategic and base metals, with an advanced stage copper oxide project in Chile and a highly prospective molybdenum property in British Columbia, Canada. GBLHF teams are working on developing the Corona de Cobre property in Chile and the Rabbit south property in British Columbia.
Global Hunter Corp. (GBLHF.PK) is pleased to announce initial assay results from its previously announced surface sampling program. The results are encouraging with new gold showings as well as very positive copper oxide assays over wide-spread areas.
Highlights of the entire program
9 mineralized shear and/or alteration zones sampled total of 13.5 kilometers of strike length along know copper bearing shear and alteration zones tested with 205 rock chip samples
Good grades of soluble copper (oxide) over a significantly large area have been identified, however they represent only about 50% of the total copper grade indicating a mixed oxide-sulphide zone. Numerous iron oxide structures have also been mapped but no iron assays have been received to date.
The Company is planning to re-assay samples for iron to determine if iron is present in significant quantities to represent another target
For more information http://www.gl! obalhunt er.ca/homeabout.html
Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that it has launched a pivotal, randomized, double-blind, controlled Phase 3 trial of rindopepimut in patients with surgically resected epidermal growth factor variant III (EGFRvIII)-positive glioblastoma, the “ACT IV Study.” US investigators have started screening patients for inclusion in the trial that is expected to enroll up to 440 patients internationally to recruit 374 patients with Gross Total Resection (GTR) for the primary analysis. Rindopepimut is a therapeutic cancer vaccine candidate that targets the tumor-specific oncogene EGFRvIII, which confers an enhanced capacity for unregulated tumor growth and which is present in many cancer cell types, but not present at significant levels in normal cells. Expression of EGFRvIII is linked to poor long term survival regardless of other factors such as extent of resection and age. EGFRvIII has been shown by polymerase chain reaction (PCR) analysis to be expressed in approximately 31% of glioblastoma tumors.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in the development, manufacture, and commercialization of novel therapeutics for human health care.
Vitran Corp Inc. (Nasdaq:VTNC) a North American transportation and supply chain firm, announced that it has signed and closed the two previously-announced credit agreements, replacing the current credit agreement which was due to expire in 2012. Vitran signed a new, three-year bank agreement with a four-bank syndicate led by JPMorgan Chase Bank, for an asset-based revolving credit facility to provide up to $85 million. Vitran also signed a new $45.7 million seven-year real estate term credit facility secured by Vitran’s four Canadian LTL transportation facilities.
Vitran Corporation Inc. provides freight surface transportation and related supply chain services in Canada and the United States.
Brooks Automation Inc. (Nasdaq:BRKS)! announced that the company will present at the Barclays Capital 2011 Global Technology Conference in San Francisco. Martin Headley, Brooks Executive Vice President and CFO, will present on Thursday, December 8th at 11:30 a.m. Pacific Time. Analysts, investors and members of the media can access the presentation via the Brooks website at www.brooks.com
Brooks Automation, Inc. provides automation, vacuum, and instrumentation solutions for semiconductor manufacturing, life sciences, and clean energy markets worldwide. The company�s Brooks Product Solutions segment provides a range of products critical to technology equipment productivity and availability.
No comments:
Post a Comment